Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Crizotinib + PLX4720|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Crizotinib||Xalkori||PF-02341066||ALK Inhibitor 29 BCR-ABL Inhibitor 29 MET Inhibitor 56 RON Inhibitor 11 ROS1 Inhibitor 19||Xalkori (crizotinib) inhibits ALK kinase, ALK fusion proteins, c-Met, ROS1 fusion proteins, and MST1R (RON), resulting in growth inhibition of tumor cells (PMID: 26951079, PMID: 22617245). Xalkori (crizotinib) is FDA approved for use in patients with ALK- or ROS1-positive (rearrangements and fusions) metastatic non-small cell lung cancer, in pediatric patients 1 year and older and young adults with relapsed or refractory, ALK-positive systemic anaplastic large cell lymphoma, and in adult and pediatric patients 1 year and older with ALK-positive, unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (FDA.gov).|
|PLX4720||PLX-4720|PLX 4720||BRAF Inhibitor 21||PLX4720 is a 7-azaindole derivative and RAF kinase inhibitor with greater affinity for BRAF V600E than BRAF wild-type, which may induce cell cycle arrest and apoptosis, and lead to tumor growth inhibition and regression (PMID: 18287029).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|